GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
147% more call options, than puts
Call options by funds: $62.7M | Put options by funds: $25.3M
81% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 32
44% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 59
39% more capital invested
Capital invested by funds: $1.81B [Q4 2024] → $2.51B (+$701M) [Q1 2025]
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
15.32% more ownership
Funds ownership: 85.66% [Q4 2024] → 100.98% (+15.32%) [Q1 2025]
12% more funds holding
Funds holding: 199 [Q4 2024] → 223 (+24) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$78
21%
upside
Avg. target
$89
38%
upside
High target
$110
70%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Jefferies Tycho Peterson | 24%upside $80 | Buy Upgraded | 9 May 2025 |
TD Securities Dan Brennan | 70%upside $110 | Buy Maintained | 1 May 2025 |
Wells Fargo Brandon Couillard | 21%upside $78 | Equal-Weight Maintained | 1 May 2025 |
Financial journalist opinion
Based on 9 articles about WGS published over the past 30 days
Neutral
PRNewsWire
1 day ago
INVESTIGATION ALERT: Edelson Lechtzin LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) and Encourages Investors with Substantial Losses to Contact the Firm
NEWTOWN, Pa. , June 13, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving GeneDx Holdings Corp. ("GeneDx") (NASDAQ: WGS), resulting from allegations of providing potentially misleading business information to the investing public.
Neutral
PRNewsWire
2 days ago
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES , June 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GeneDx Holdings Corp. ("GeneDx" or "the Company") (NASDAQ: WGS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Business Wire
2 days ago
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGS
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Schaeffers Research
2 days ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Neutral
Business Wire
3 days ago
WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
3 weeks ago
GeneDx to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences.
Neutral
Business Wire
3 weeks ago
GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced the publication of a new article demonstrating the company's leadership in applying AI to accelerate and enhance genetic diagnostics.
Positive
Seeking Alpha
3 weeks ago
GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality, adverse weather, and one fewer business day, not a structural slowdown; fundamentals remain robust. Strong pricing power and rising reimbursement rates drive revenue growth, setting a solid foundation for future acceleration as volumes rebound.
Positive
Seeking Alpha
1 month ago
GeneDx: Time To Buy The Dip
GeneDx's recent 50% stock drop post-Q1 earnings is seen as an overreaction, despite a projected modest growth slowdown from 42% to 30-35%. The company is expanding product lines, improving margins, and increasing insurance coverage, with the recent acquisition of Fabric Genomics offering growth and cost synergies. GeneDx's valuation is attractive compared to peers, with a forward P/E of 30 and projected profitability next year, unlike Natera and Tempus AI.
Charts implemented using Lightweight Charts™